Brain FAAH Levels Rise During Short-Term Cannabis Abstinence

The Neurobiological Hurdle of Cannabis Withdrawal

Cannabis use disorder remains a significant clinical challenge characterized by a high rate of relapse during the acute withdrawal phase, yet effective pharmacological treatments remain elusive. The endocannabinoid system, which regulates stress, reward, and affective processes, undergoes substantive molecular shifts in chronic users, including global reductions in metabolic enzymes and receptor availability [1, 2]. While previous research has established that cannabis exposure alters brain metabolism and dopaminergic synthesis capacity, the specific temporal dynamics of the system during the transition to abstinence are poorly understood [1, 3]. Dysregulation of this system is frequently linked to the emotional instability and impaired impulse control that complicate recovery in various substance use disorders [4, 5]. A recent longitudinal study using positron emission tomography now provides specific data on how the brain's enzymatic environment shifts during the first week of cessation, offering a potential explanation for the psychological distress patients experience when attempting to quit [6].

Quantifying Enzymatic Shifts via PET Imaging

The researchers conducted a longitudinal study to investigate changes in fatty acid amide hydrolase (FAAH) levels during short-term abstinence and their relationship with withdrawal symptoms. The study initially enrolled 17 participants with cannabis use disorder, though the final sample included 14 participants who completed both positron emission tomography (PET) scans following attrition. To quantify FAAH levels, the team utilized the FAAH-specific radiotracer [11C]CURB. They determined the specific binding of this tracer across whole-brain regions of interest by applying an irreversible two-tissue compartment model, a mathematical kinetic analysis method used to accurately quantify radiotracer uptake in brain tissue.

The imaging protocol involved two distinct time points to capture the neurobiological transition during early cessation. Participants underwent an initial PET scan (T1) after overnight abstinence. A second scan (T2) was performed approximately 3 to 7 days after the monitored last use of cannabis. To account for inherent biological differences, the researchers analyzed blood samples to determine each patient's FAAH polymorphism (rs324420), a genetic variation known to influence baseline enzyme activity. Alongside the imaging data, the study included comprehensive clinical assessments to evaluate mood, cognition, withdrawal symptoms, and craving. This multifaceted approach allowed the authors to correlate enzymatic shifts directly with the subjective and behavioral challenges patients face during the critical first week of abstinence.

Upregulation in the Reward Circuitry

The longitudinal analysis revealed that FAAH binding in the whole brain increased by 10% between the initial scan and the follow-up (n = 14; p = 0.003). This finding demonstrates that short-term cannabis abstinence is associated with rapid increases in brain FAAH levels as exogenous cannabinoids clear the system. Because FAAH is the primary enzyme responsible for degrading anandamide, a major endogenous cannabinoid that regulates mood and reward, this upregulation likely creates a state of endocannabinoid deficiency during the critical first week of cessation.

Regional analysis pinpointed specific areas where these enzymatic shifts were most pronounced. The researchers observed that the largest regional change in FAAH binding occurred in the ventral striatum, which showed an 11% increase (p = 0.026). The ventral striatum is a core component of the brain's reward circuitry, and its heavy involvement suggests that the neurobiological changes during withdrawal are concentrated in areas governing motivation and pleasure. Furthermore, the magnitude of these enzymatic changes was not uniform across the study period. Instead, increases in whole-brain FAAH binding were significantly associated with a longer duration of cannabis abstinence (p < 0.001), indicating that the enzymatic upregulation intensifies as the withdrawal period progresses through the first week.

These neurobiological shifts appear to have direct clinical implications for patient management during the withdrawal phase. The study found that the increases in whole-brain FAAH levels were significantly associated with greater baseline depression severity and a higher tendency to act without thinking, a clinical measure of impulsivity (p < 0.001). For the practicing clinician, these data suggest that the first 3 to 7 days of abstinence represent a period of significant neurochemical flux in the reward system. The rise in FAAH levels during this window may drive the negative affect and behavioral disinhibition that often lead to treatment nonadherence and relapse.

Clinical Correlates of Relapse Vulnerability

The clinical utility of tracking fatty acid amide hydrolase (FAAH) levels lies in their direct correlation with the behavioral and affective challenges patients face during the first week of cessation. In this study of 14 participants with cannabis use disorder, the researchers found that these neurobiological shifts were tied directly to the psychological state of the patient. Specifically, increases in whole-brain FAAH binding were significantly associated with greater baseline depression severity (p < 0.001). This suggests that patients entering treatment with higher levels of depressive symptoms may experience a more pronounced enzymatic surge. This surge potentially leads to a deeper deficiency in anandamide, the endogenous cannabinoid responsible for mood regulation, during the acute withdrawal phase.

Beyond mood disturbances, the enzymatic upregulation also appears to drive behavioral disinhibition. The data indicated that increases in whole-brain FAAH binding were significantly associated with a tendency to act without thinking, a clinical measure of impulsivity (p < 0.001). For the practicing physician, this finding provides a neurobiological basis for the poor inhibitory control often observed in patients during early abstinence. Because FAAH increases are linked to traits and symptoms associated with relapse vulnerability, including negative mood and impulsivity, these results highlight a critical window for intervention. The rise in FAAH levels between 3 and 7 days of abstinence may represent a primary driver of the distress that leads to treatment nonadherence, suggesting that the enzyme could serve as a specific pharmacological target to improve outcomes in cannabis use disorder.

Implications for Pharmacological Intervention

The identification of enzymatic shifts during early abstinence addresses a critical gap in the management of cannabis use disorder, a condition where cannabis withdrawal increases the risk of relapse and currently lacks effective treatments. Because the endocannabinoid enzyme fatty acid amide hydrolase (FAAH), which breaks down the mood-regulating lipid signaling molecule anandamide, may influence cannabis use and withdrawal, it has emerged as a primary focus for therapeutic development. The study findings suggest that the 10% increase in whole-brain FAAH binding (p = 0.003) and the 11% increase in the ventral striatum (p = 0.026) observed in the 14 participants who completed the protocol are not merely incidental. Instead, these elevations represent a specific neurobiological response to short-term abstinence that likely exacerbates the withdrawal syndrome.

For the practicing clinician, these results provide a rationale for exploring new medication classes that move beyond symptomatic relief. The researchers suggest that FAAH may represent a potential target for pharmacological interventions during the neurobiological response to short-term abstinence, as inhibiting this enzyme could theoretically prevent the rapid degradation of endogenous cannabinoids and stabilize the reward circuitry. By mitigating the enzymatic surge that correlates with depression and impulsivity (p < 0.001), such interventions might reduce the physiological drive to resume cannabis use. Identifying these neurobiological markers for relapse risk during the first 3 to 7 days of cessation offers a concrete window for medical management, potentially improving the standard of care for patients struggling with persistent cannabis use disorder.

References

1. Xu H, Owens MM, Farncombe T, Noseworthy M, MacKillop J. Molecular brain differences and cannabis involvement: A systematic review of positron emission tomography studies.. Journal of psychiatric research. 2023. doi:10.1016/j.jpsychires.2023.03.045

2. Sloan ME, Grant CW, Gowin JL, Ramchandani VA, Foll BL. Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies.. Acta pharmacologica Sinica. 2019. doi:10.1038/s41401-018-0081-z

3. Batalla A, Bhattacharyya S, Yücel M, et al. Structural and Functional Imaging Studies in Chronic Cannabis Users: A Systematic Review of Adolescent and Adult Findings. PLoS ONE. 2013. doi:10.1371/journal.pone.0055821

4. Costa GPA, Cerezo-Matias MA, Funaro MC, et al. Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies. Molecular Psychiatry. 2026. doi:10.1038/s41380-026-03523-5

5. McPartland JM, Guy GW, Marzo VD. Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. PLoS ONE. 2014. doi:10.1371/journal.pone.0089566

6. Poluga C, Dheda SS, Boachie N, et al. PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2026. doi:10.1038/s41386-026-02438-7